Evidence map›Paper›PMID 39989079›Full record

ArticleBritish journal of clinical pharmacology2025

Effect of hydration schedules on dose-limiting toxicity in patients with head and neck squamous cell carcinoma treated with cisplatin.

Anouk W M A Schaeffers, Cassimy B van Neerven, Dorieke van Balen, Mirjam Crul, Marije Slingerland, Saskia A C Luelmo, Jan Paul de Boer, Jens Voortman, Arjan D van Zuilen, Remco de Bree and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Anouk W M A SchaeffersDepartment of Head and Neck Surgical Oncology, Division Imaging and Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.ORCID https://orcid.org/0000-0002-7952-8734
Cassimy B van NeervenDepartment of Pharmacology, Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
Dorieke van BalenDepartment of Pharmacology, Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
Mirjam CrulDepartment of Clinical Pharmacology and Pharmacy, Amsterdam University Medical Center, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0002-4929-2388
Marije SlingerlandDepartment of Medical Oncology, Leiden University Medical Center Leiden, Leiden, The Netherlands.
Saskia A C LuelmoDepartment of Medical Oncology, Leiden University Medical Center Leiden, Leiden, The Netherlands.
Jan Paul de BoerDepartment of Medical Oncology, Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
Jens VoortmanDepartment of Medical Oncology, Amsterdam UMC, location VUmc, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Arjan D van ZuilenDepartment of Nephrology, Division of Internal Medicine, Dermatology, Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, The Netherlands.
Remco de BreeDepartment of Head and Neck Surgical Oncology, Division Imaging and Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Lot A DevrieseDepartment of Medical Oncology, Division Imaging and Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThe aim of this study was to determine if head and neck squamous cell carcinoma (HNSCC) patients treated with cisplatin chemoradiotherapy and short hydration (SH) experience less dose-limiting toxicity (DLT) and receive more cisplatin than those with medium hydration (MH) or long hydration (LH).

methodsBaseline characteristics, cumulative cisplatin dose and toxicities were collected. Differences between LH, MH and SH were tested, with separate analyses for triweekly 100 mg/m

resultsA total of 389 patients were included. DLT occurrence was comparable between hydration groups (P = .060), but DLT type differed (P = .007). Nephrotoxicity was common with LH and MH (n = 11, 61% and n = 26, 45%, respectively), and ototoxicity with SH (n = 35, 36%). DLT occurrence in triweekly patients differed between LH and MH (n = 18, 64% vs n = 25, 32%, P = .004), but not between MH and SH (P = .171) or LH and SH (P = .055) patients. Cisplatin dose differed between LH and MH (median 200 vs 300, P = .008) as well as between LH and SH (median 200 vs 300, P = .024) but not between MH and SH (P = .429) patients. Hydration had no effect on dose (F = 2.09, P = .125).

conclusionsDLT cause differed between hydration groups, with less nephrotoxicity but more ototoxicity in HNSCC patients with SH. Triweekly cisplatin LH patients had more DLT and lower cumulative dose compared to MH and SH, but no hydration effect in general on dose was found.

Indexed as

Antineoplastic AgentsCisplatinFluid TherapyHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and NeckAdultAgedChemoradiotherapyDose-Response Relationship, DrugDrug Administration ScheduleFemaleHumansMaleMiddle AgedOtotoxicityRetrospective StudiesAntineoplastic AgentsCisplatinchemoradiotherapycisplatindose‐limiting toxicityhead and neck oncologyhydrationnephrotoxicity

Identifiers

PMID39989079
PMCPMC12199115

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.